Private Equity company Carlyle has acquired Abingworth, a transatlantic life sciences investment firm with over $2bn worth of assets. The deal will enable Carlyle to operate across the full spectrum of life sciences and healthcare investing.
Join our network of executives who receive the MBS News daily, as well as the insights, analysis and our weekly column in The Weekend Edition.
You’ll be able to unsubscribe at any time.